Neuropsychiatric symptoms at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

18 organizations at CTAD 2026 present work in neuropsychiatric symptoms, led by universities and research institutes. Between them they bring 45 presentations to the program. Most represented: USC Alzheimer's Therapeutic Research Institute, McLean Hospital and Indiana University. As of Oct 8, 2026.

All 315 organizations at CTAD 2026 →

Showing 1–11 of 18 organizations

Organization	CTAD 2026 Attendance
USC Alzheimer's Therapeutic Research Institute San Diego, California
atri.usc.edu Universities & institutes USC academic center that designs, coordinates and analyzes Alzheimer's trials such as A4 and AHEAD; part of the Alzheimer's Clinical Trials Consortium.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Site Engagement Within a Centralized Recruitment, Engagement, and Retention Framework: The Alzheimer’s Clinical Trials Consortium Experience (P179) Trial design and endpoints Session Mon Nov 16 3:15pm–3:25pm Welcome Ceremony and CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research with Brigham and Women's Hospital, Toulouse University Hospital, Imperial College London +3 more Session Tue Nov 17 11:05am–11:45am Remote Digital Biomarkers in Alzheimer’s Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment Digital assessment and AI · Trial design and endpoints · with University of California, San Francisco Talk Wed Nov 18 8:30am Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Disaggregating Asian Populations in a Global Preclinical Alzheimer’s Disease Trial: Recruitment, Screening and Randomization in the AHEAD 3-45 Study (P363) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Plasma p-tau217 In Early Alzheimer’s Disease Trial Screening: Insights from START (P365) Blood and CSF biomarkers · Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Leveraging Anti-Amyloid Clinical Trial Screening to Establish a Longitudinal Primary Prevention Cohort: APEX Recruitment Strategy and Baseline Findings (P375) Prevention and early disease · Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials (P391) Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Promoting dementia research participation in high-risk communities – co-creating a Research Ambassador Program. (P445) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Baseline Completion and Retention with a New Cognitive Assessment in an Online Alzheimer’s Disease Trial Registry: Results from the APT Webstudy (P502) Digital assessment and AI · Trial design and endpoints Talk Thu Nov 19 8:30am–9:10am Part of Lessons from The Life’s end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia Advancing Trials in Dementia: Lessons from LiBBY and a Future Research Agenda for the Alzheimer’s Clinical Trial Consortium (ACTC) Trial design and endpoints · Neuropsychiatric symptoms Talk Thu Nov 19 10:40am–11:05am Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials Blood and CSF biomarkers · with Emory University Talk Thu Nov 19 2:50pm Biomarker Associations and Outcome Performance in Preclinical Alzheimer Disease Trials Trial design and endpoints · Prevention and early disease Talk Thu Nov 19 3:20pm Cross-platform performance of plasma p-tau217 assays for predicting amyloid PET positivity across cohorts Blood and CSF biomarkers Talk Thu Nov 19 3:35pm Plasma %p-tau217 and Aβ42/Aβ40 provide complementary information about amyloid PET below 20 Centiloids: Baseline findings from the Alzheimer’s Plasma Extension Study Blood and CSF biomarkers
McLean Hospital Belmont, Massachusetts
mcleanhospital.org Hospitals & health systems Harvard-affiliated psychiatric hospital near Boston, part of Mass General Brigham, with a geriatric psychiatry research programme.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Caring for Behavioral Symptoms of Dementia (CBD): Pilot Trial of Cannabidiol for Anxiety in Patients with Mild Cognitive Impairment and Alzheimer’s Dementia (P061) Neuropsychiatric symptoms Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Nicotinamide Riboside Supplementation in Mild Cognitive Impairment and Mild Alzheimer’s Disease: Target Engagement and Downstream Effects of Mitochondrial Function and Oxidative Stress (P075) Other mechanisms and targets Poster Thu Nov 19 7:15am–5:00pm Pragmatic Barriers to Inclusivity in Geriatric Clinical Trials (P378) Trial design and endpoints
Indiana University Bloomington, Indiana
iu.edu Universities & institutes Its medical school in Indianapolis hosts an NIA-funded Alzheimer's Disease Research Center.	Talk Tue Nov 17 2:35pm–3:15pm Part of Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk Central-Peripheral Neuroimmune Crosstalk: Targeting Immune Dysfunction to Reduce Neurodegenerative Disease Progression Other mechanisms and targets Session Tue Nov 17 2:35pm–3:15pm Neuroinflammation in Alzheimer’s Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm A Care Coach protocol for caregivers of persons with dementia (PWD) to help manage behavioral and psychological symptoms of dementia (BPSD). (P203) Neuropsychiatric symptoms Poster Wed Nov 18 7:15am–5:30pm Factors contributing to retention in a mobile telehealth intervention trial for dementia caregivers. (P204) Trial design and endpoints · Digital assessment and AI
Bristol Myers Squibb Princeton, New Jersey	◆Gold Sponsor
bms.com Large pharmaGold Sponsor Global drugmaker testing Cobenfy for psychosis in Alzheimer's disease and developing an anti-tau antibody, among other neuroscience programs.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Results from 2 phase 1 studies evaluating the dual FAAH/MAGL inhibitor irafamdastat in healthy adults (including Japanese and elderly) (P049) Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer’s Disease (P326) Other mechanisms and targets
Signant Health Blue Bell, Pennsylvania	◇Silver Sponsor
signanthealth.com CROs & trial servicesSilver Sponsor eCOA and clinical-outcome-assessment provider that trains and monitors raters and reviews scale data quality in Alzheimer's trials.	Poster Thu Nov 19 7:15am–5:00pm Most Screening–Baseline MMSE Variability Is Individual Noise: Pooled Analysis of 17 Alzheimer’s Trials (P395) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Understanding NPI-C Rating Errors in AD Psychosis Trials: A Multi-Study Analysis of Hallucination and Delusion Domain Flags (P430) Neuropsychiatric symptoms · Trial design and endpoints
Georgetown University Washington, DC
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Burden Profiles by Caregiver Sex Among Hospice-Eligible Persons Living with Dementia: A Secondary Analysis of the LiBBY Phase II Trial (P155) Real-world data and access Talk Thu Nov 19 8:30am–9:10am Part of Lessons from The Life’s end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia Effects of THC/CBD on NPI-Q Agitated Symptoms in Advanced Dementia: Results from the Double-Blind, Placebo-Controlled LiBBY Study Neuropsychiatric symptoms
Medical University of South Carolina Charleston, South Carolina
	Talk Thu Nov 19 8:30am–9:10am Part of Lessons from The Life’s end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia Domain-Specific Effects of THC/CBD on Agitation in Advanced Dementia: Cohen-Mansfield Agitation Inventory Analyses from the LiBBY Study Presentation Neuropsychiatric symptoms Session Thu Nov 19 8:30am–9:10am Lessons from The Life’s end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia Neuropsychiatric symptoms
Suven Life Sciences Hyderabad, India
suven.com Biotech Indian drug developer running a phase 3 trial of masupirdine, a 5-HT6 antagonist, for agitation in Alzheimer's dementia.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer’s type (P033) Neuropsychiatric symptoms Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects (P066) Other mechanisms and targets
University of Nevada, Las Vegas Las Vegas, Nevada
	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue TREMHANCE: A Phase 2 study to evaluate the efficacy and safety of TREM2 agonist SAR448851 in early Alzheimer’s disease (P059) Other mechanisms and targets Talk Mon Nov 16 3:25pm–3:50pm New Molecules in Phase 2b – Proof of Concept and Beyond Trial design and endpoints · with IHU HealthAge Talk Tue Nov 17 9:35am Efficacy and Safety of Remlifanserin in Patients With Alzheimer’s Disease Psychosis Neuropsychiatric symptoms Talk Wed Nov 18 9:00am Psychosis symptoms associated with AD improve with short- and long-term open-label KarXT treatment Neuropsychiatric symptoms
Acadia Pharmaceuticals San Diego, California	◇Silver Sponsor
acadia.com BiotechSilver Sponsor Develops and markets neuroscience medicines, including pimavanserin (Nuplazid) for Parkinson's disease psychosis, and studies treatments for neuropsychiatric symptoms.	Poster Wed Nov 18 7:15am–5:30pm Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer’s Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217 (P303) Neuropsychiatric symptoms · Blood and CSF biomarkers
Alpha Cognition Grapevine, Texas
alphacognition.com Biotech Markets Zunveyl (benzgalantamine), an oral cholinesterase-inhibitor prodrug for mild to moderate Alzheimer's dementia.	Poster Thu Nov 19 7:15am–5:00pm The Effects of Benzgalantamine (ZUNVEYL®) on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in the Treatment of Mild to Moderate Alzheimer’s Dementia. RESOLVE: a Phase IV Open-label Study (P396) Other mechanisms and targets · Neuropsychiatric symptoms

Instantly find 20 buyers in neuropsychiatric symptoms

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse CTAD 2026 by

Organization type

Topic

Everyone

All organizations A–Z 315

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction